Company news
Novo Nordisk A/s Class B (OMXCOP:NOVO_B) news
Every Novo Nordisk A/s Class B press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Novo Nordisk A/S: IT Security incident at Novo Nordisk
June 11, 2026
Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK
June 11, 2026
Novo Nordisk introduces updated Rybelsus® tablet formulation in Canada for adults living with type 2 diabetes
June 9, 2026
Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care
June 3, 2026
Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association's 2...
May 27, 2026
Novo Nordisk Introduces Extra Savings for Canadians Who Choose Ozempic®
May 26, 2026
Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing th...
May 26, 2026
Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)
May 22, 2026
Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the mos...
May 22, 2026
Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and...
May 19, 2026
Novo Nordisk Canada and Rexall Pharmacy partner to offer convenience, support, and home delivery for Canadians taking Ozempic® and Wegovy®
May 13, 2026
Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, sho...
May 12, 2026
Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the ...
May 12, 2026
Cellular Intelligence, an AI-native TechBio, Enters Agreement with Novo Nordisk to Advance Clinical-Stage Parkinson's Cell Therapy
May 11, 2026
Prothena Reports First Quarter 2026 Financial Results and Business Highlights
May 7, 2026
Amazon Pharmacy Expands Access to New Ozempic® Pill via Same-Day Delivery, Kiosks
May 7, 2026
Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 7, 2026
As AI Rewrites Drug Development, the Industry Gathers in Philadelphia to Work Out the Rules
May 6, 2026
Novo Nordisk's adjusted operating profit reached DKK 32,858 million in Q1 2026
May 6, 2026
Novo Nordisk A/S - share repurchase programme
May 5, 2026
Novo Nordisk's Ozempic® pill, the only FDA-approved oral peptide GLP-1 medication for adults with type 2 diabetes, soon to be available i...
May 1, 2026
Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started
April 29, 2026
Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity
April 28, 2026
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomy...
April 27, 2026
Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 dia...
April 23, 2026
Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantia...
April 20, 2026
Novo Nordisk and OpenAI partner to transform how medicines are discovered and delivered
April 14, 2026
Novo Nordisk A/S: Wegovy® injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU
April 9, 2026
Novo Nordisk's Wegovy® HD available now nationwide
April 7, 2026
Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indire...
April 2, 2026
RO HELPS PATIENTS SAVE UP TO $1,200 PER YEAR ON WEGOVY® THROUGH COLLABORATION WITH NOVO NORDISK
March 31, 2026
Weight Watchers Announces Best in Market Self-Pay Wegovy® Pricing for Med+ Members and the Launch of Preferred Subscription Pricing for W...
March 31, 2026
Novo Nordisk launches first and only multi-month subscription program for FDA-approved Wegovy®, offering savings of up to $1,200/year
March 31, 2026
Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
March 26, 2026
Resolutions from the Annual General Meeting of Novo Nordisk A/S
March 26, 2026
Novo Nordisk A/S: Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients ...
March 25, 2026
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
March 23, 2026
FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its a...
March 19, 2026
Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss
March 19, 2026
WHO Foundation and Novo Nordisk Expand Collaboration to Provide Financial Support towards strengthening health systems for Cardio-Renal-M...
March 11, 2026
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for ...
March 9, 2026
Hims & Hers Announces Strategic Shift for US Weight Loss Business
March 9, 2026
Election of employee representatives to the Board of Directors of Novo Nordisk A/S
March 2, 2026
Novo Nordisk announces more than 400 million euro expansion in its manufacturing facility in Athlone, Ireland
March 2, 2026
Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes
February 25, 2026
Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on c...
February 24, 2026
Novo Nordisk: Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China
February 24, 2026
Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the prima...
February 23, 2026
Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S
February 20, 2026
Goodpath Expands Direct-to-Employer and Self-Pay Access to Wegovy Through Novo Nordisk Collaboration
February 18, 2026